Verrica Pharmaceuticals Inc. Stock price

Equities

VRCA

US92511W1080

Pharmaceuticals

Market Closed - Nasdaq 03:59:53 2024-03-28 pm EDT 5-day change 1st Jan Change
5.92 USD +4.78% Intraday chart for Verrica Pharmaceuticals Inc. +17.23% -19.13%
Sales 2024 * 23.95M Sales 2025 * 72.18M Capitalization 240M
Net income 2024 * -76M Net income 2025 * -39M EV / Sales 2024 * 10 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 3.32 x
P/E ratio 2024 *
-3.64 x
P/E ratio 2025 *
-7.15 x
Employees 100
Yield 2024 *
-
Yield 2025 *
-
Free-Float 43.45%
More Fundamentals * Assessed data
Dynamic Chart
Verrica Pharmaceuticals' Ycanth Gets New Chemical Entity Status, Orange Book Listing MT
Verrica Pharmaceuticals Announces that YCANTH? Receives New Chemical Entity Status and Orange Book Listing from the FDA CI
HC Wainwright Adjusts Verrica Pharmaceuticals Price Target to $13 From $12, Maintains Buy Rating MT
Transcript : Verrica Pharmaceuticals Inc., Q4 2023 Earnings Call, Feb 29, 2024
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (VRCA) VERRICA PHARMACEUTICALS Reports Q4 Revenue $2M, vs. Street Est of $950,000 MT
Verrica Pharmaceuticals Sues Dormer Labs for Promoting Unapproved Cantharidin Drugs in US MT
Verrica Pharmaceuticals Receives Permanent J-Code for YCANTH from Centers for Medicare and Medicaid Services CI
Ligand Pharma's at-home skin treatment gets FDA approval RE
Verrica Pharmaceuticals Inc. Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315 CI
Lytix Biopharma’s License Partner Finalizes Patient Dosing in Phase 2 Trial of Skin Cancer Therapy MT
Verrica Pharmaceuticals Doses Last Patient in Part 2 of Phase 2 Study of Potential Skin Cancer Treatment MT
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH?? for the Treatment of Common Warts CI
Verrica Pharmaceuticals Partners With Walgreens to Distribute YCANTH Therapy MT
More news
1 day+6.20%
1 week+13.91%
Current month+7.21%
1 month-0.35%
3 months-20.98%
6 months+47.91%
Current year-22.81%
More quotes
1 week
4.78
Extreme 4.78
5.80
1 month
4.60
Extreme 4.6
6.05
Current year
4.60
Extreme 4.6
7.29
1 year
2.86
Extreme 2.86
7.76
3 years
1.77
Extreme 1.77
17.00
5 years
1.77
Extreme 1.77
18.67
10 years
1.77
Extreme 1.77
23.29
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 17-11-30
Director of Finance/CFO 46 21-07-15
Compliance Officer 60 18-08-31
Members of the board TitleAgeSince
Director/Board Member 58 18-04-30
Chairman 68 15-11-30
Director/Board Member 63 19-06-12
More insiders
Date Price Change Volume
24-03-28 5.92 +4.78% 88 454
24-03-27 5.65 +6.20% 210,561
24-03-26 5.32 +5.14% 404,423
24-03-25 5.06 +1.00% 246,107
24-03-22 5.01 -0.79% 67,363

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: VP-102, VP-315 and VP-103. The Company's lead product candidate, VP-102, is a drug-device combination that contains a GMP-controlled formulation of cantharidin which is being developed for potential use in treating molluscum contagiosum, a contagious and primarily pediatric viral skin disease; external genital warts (EGW), and common warts. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma and non-metastatic Merkel cell carcinoma. The Company is also developing its second cantharidin-based product candidate, VP-103, for the treatment of plantar warts, which are warts located on the bottom of the foot.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.65 USD
Average target price
13.6 USD
Spread / Average Target
+140.71%
Consensus
  1. Stock
  2. Equities
  3. Stock Verrica Pharmaceuticals Inc. - Nasdaq